We demonstrated both in vitro and in vivo that WDR62 promotes aggressive prostate cancer phenotypes in all of the prostate cancer models that were tested, irrespective of AR-status, suggesting that this is an AR-independent human prostate cancer driver gene. Here, WDR62 is linked to prostate carcinoma.